Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.

Kanthala S, Mill CP, Riese DJ 2nd, Jaiswal M, Jois S.

Protein Expr Purif. 2016 Sep;125:26-33. doi: 10.1016/j.pep.2015.09.001. Epub 2015 Sep 9.

2.

Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.

Gallo RM, Bryant IN, Mill CP, Kaverman S, Riese DJ 2nd.

J Cancer Res Ther Oncol. 2013 Aug 22;1(1):10.

3.

Epiregulin: roles in normal physiology and cancer.

Riese DJ 2nd, Cullum RL.

Semin Cell Dev Biol. 2014 Apr;28:49-56. doi: 10.1016/j.semcdb.2014.03.005. Epub 2014 Mar 12. Review.

4.

Team-based learning in US colleges and schools of pharmacy.

Allen RE, Copeland J, Franks AS, Karimi R, McCollum M, Riese DJ 2nd, Lin AY.

Am J Pharm Educ. 2013 Aug 12;77(6):115. doi: 10.5688/ajpe776115.

6.

At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Foley J, Nickerson N, Riese DJ 2nd, Hollenhorst PC, Lorch G, Foley AM.

Odontology. 2012 Jul;100(2):109-29. doi: 10.1007/s10266-012-0070-5. Epub 2012 Jun 10. Review.

7.

ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ 2nd.

Genes Cancer. 2011 Aug;2(8):792-804. doi: 10.1177/1947601911431080.

8.

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ 2nd.

Growth Factors. 2012 Apr;30(2):107-16. doi: 10.3109/08977194.2011.649918. Epub 2012 Jan 20. Review.

9.

The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ.

Biochem J. 2012 Apr 1;443(1):133-44. doi: 10.1042/BJ20110921.

10.

A high throughput, interactive imaging, bright-field wound healing assay.

Zordan MD, Mill CP, Riese DJ 2nd, Leary JF.

Cytometry A. 2011 Mar;79(3):227-32. doi: 10.1002/cyto.a.21029. Epub 2011 Feb 9.

11.
12.

Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Mill CP, Gettinger KL, Riese DJ 2nd.

Exp Cell Res. 2011 Feb 15;317(4):392-404. doi: 10.1016/j.yexcr.2010.11.007. Epub 2010 Nov 24.

13.

EGFR signaling in breast cancer: bad to the bone.

Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ 2nd.

Semin Cell Dev Biol. 2010 Dec;21(9):951-60. doi: 10.1016/j.semcdb.2010.08.009. Epub 2010 Sep 9. Review.

14.

Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.

Gilmore JL, Gonterman RM, Menon K, Lorch G, Riese DJ 2nd, Robling A, Foley J.

Mol Cancer Res. 2009 Oct;7(10):1714-28. doi: 10.1158/1541-7786.MCR-09-0131. Epub 2009 Oct 13.

15.

Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase.

Coon BG, Mukherjee D, Hanna CB, Riese DJ 2nd, Lowe M, Aguilar RC.

Hum Mol Genet. 2009 Dec 1;18(23):4478-91. doi: 10.1093/hmg/ddp407. Epub 2009 Aug 21.

PMID:
19700499
16.

Functional selectivity of EGF family peptide growth factors: implications for cancer.

Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd.

Pharmacol Ther. 2009 Apr;122(1):1-8. doi: 10.1016/j.pharmthera.2008.11.008. Epub 2008 Dec 16. Review.

17.

EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Mill CP, Chester JA, Riese DJ 2nd.

Breast Cancer (Dove Med Press). 2009 Oct 5;1:31-8. Review.

18.

Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ 2nd, McCorvy JD, Chester JA, Nichols DE, Watts VJ.

Eur Neuropsychopharmacol. 2009 Feb;19(2):138-46. doi: 10.1016/j.euroneuro.2008.10.002. Epub 2008 Nov 22.

19.

Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.

Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ 2nd, Ethier SP.

Cell Signal. 2009 Feb;21(2):212-9. doi: 10.1016/j.cellsig.2008.10.003. Epub 2008 Oct 14.

20.

Modeling oncogene addiction using RNA interference.

Rothenberg SM, Engelman JA, Le S, Riese DJ 2nd, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4. doi: 10.1073/pnas.0803217105. Epub 2008 Aug 18.

21.

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE.

Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14.

22.

The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Gallo RM, Riese DJ 2nd.

Growth Factors. 2007 Oct;25(5):329-33. doi: 10.1080/08977190701804008.

23.

Inter-conversion of neuregulin2 full and partial agonists for ErbB4.

Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ 2nd.

Biochem Biophys Res Commun. 2007 Dec 14;364(2):351-7. Epub 2007 Oct 11.

24.

Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.

Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ 2nd, Foley J.

Breast Cancer Res Treat. 2008 Aug;110(3):493-505. Epub 2007 Sep 20.

25.

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.

Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, Settleman J, Haber DA.

Cancer Res. 2007 Aug 1;67(15):7319-26.

26.
27.
28.

Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ 2nd.

Biochem Biophys Res Commun. 2006 Oct 13;349(1):372-82. Epub 2006 Aug 18.

30.
31.

Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.

VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ 2nd.

J Med Chem. 2005 Nov 17;48(23):7445-56.

PMID:
16279804
32.

secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation.

Gilmore JL, Riese DJ 2nd.

Oncol Res. 2004;14(11-12):589-602.

PMID:
15667000
33.

Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.

Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ 2nd.

Oncogene. 2004 Jan 29;23(4):883-93.

PMID:
14661053
34.

A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.

Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, Penington DJ, Riese DJ 2nd.

Cancer Lett. 2003 Mar 20;192(1):67-74.

PMID:
12637154
35.

c-Cbl-dependent EphA2 protein degradation is induced by ligand binding.

Walker-Daniels J, Riese DJ 2nd, Kinch MS.

Mol Cancer Res. 2002 Nov;1(1):79-87.

36.

Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation.

Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ 2nd.

Oncogene. 2002 Dec 5;21(55):8442-52.

37.

Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.

Penington DJ, Bryant I, Riese DJ 2nd.

Cell Growth Differ. 2002 Jun;13(6):247-56.

38.

ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.

Feroz K, Williams E, Riese DJ 2nd.

Cell Signal. 2002 Sep;14(9):793-8.

PMID:
12034361
39.

Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.

Mu F, Coffing SL, Riese DJ 2nd, Geahlen RL, Verdier-Pinard P, Hamel TE, Johnson J, Cushman M.

J Med Chem. 2001 Feb 1;44(3):441-52.

PMID:
11462983
40.

Ligand discrimination in signaling through an ErbB4 receptor homodimer.

Sweeney C, Lai C, Riese DJ 2nd, Diamonti AJ, Cantley LC, Carraway KL 3rd.

J Biol Chem. 2000 Jun 30;275(26):19803-7.

41.

Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.

Riese DJ 2nd, Komurasaki T, Plowman GD, Stern DF.

J Biol Chem. 1998 May 1;273(18):11288-94.

42.

Specificity within the EGF family/ErbB receptor family signaling network.

Riese DJ 2nd, Stern DF.

Bioessays. 1998 Jan;20(1):41-8. Review.

PMID:
9504046
43.

Ligands for ErbB-family receptors encoded by a neuregulin-like gene.

Chang H, Riese DJ 2nd, Gilbert W, Stern DF, McMahan UJ.

Nature. 1997 May 29;387(6632):509-12.

PMID:
9168114
44.

Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells.

Kannan S, De Santis M, Lohmeyer M, Riese DJ 2nd, Smith GH, Hynes N, Seno M, Brandt R, Bianco C, Persico G, Kenney N, Normanno N, Martinez-Lacaci I, Ciardiello F, Stern DF, Gullick WJ, Salomon DS.

J Biol Chem. 1997 Feb 7;272(6):3330-5.

45.
46.
47.

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Riese DJ 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF.

Mol Cell Biol. 1995 Oct;15(10):5770-6. Erratum in: Mol Cell Biol 1996 Feb;16(2):735.

49.

Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene.

Hwang ES, Riese DJ 2nd, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D.

J Virol. 1993 Jul;67(7):3720-9.

50.

Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16.

Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ 2nd, Dotto GP, DiMaio D.

J Virol. 1991 Dec;65(12):7078-83. Erratum in: J Virol 1992 Mar;66(3):1833.

Supplemental Content

Loading ...
Support Center